Publication Year: 2015
-
Hypothesis independent test development using mass spectrometry data from patient clinical groups reveals underlying biological pathways
-
Development of a Rapid Blood-based Test for EGFR Sensitizing and Resistance Mutations in NSCLC
-
Rapid Blood-based Tests for ALK, RET and ROS1 mRNA Fusions and Somatic Variants in NSCLC
-
Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
-
Comparative assessment of MALDI-TOF platforms for utility in CDx development of a proteomic signature for ficlatuzumab
-
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
-
A mass spectrometry based serum test for the detection of hepatocellular carcinoma (HCC) in high risk patients
-
A mass spectrometry-based serum protein test for prognosis of patients with MDS
-
A panel of mass spectrometry based serum protein tests for predicting Graft-versus-Host Disease (GvHD) and its severity
-
Retrospective Evaluation of the Randomized, Phase 3 MARQUEE Trial of Tivantinib (T) + Erlotinib (E) vs Placebo (P) + Erlotinib (E) Using VeriStrat in Patients With Previously Treated Non-Squamous NSCLC